C12Y 301/03048
Protein-tyrosine-phosphatase
Official title: Protein-tyrosine-phosphatase (3.1.3.48)
C12Y301/03048 (Protein-tyrosine-phosphatase) appears on 204 US grants and 463 published applications in this corpus.
Search patents in C12Y- Granted patents
- 204
- Published applications
- 463
- Assignees
- 187
- Inventors
- 592
- Latest grant
- 18 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1998 | 2 | 0 |
| 1999 | 0 | 0 |
| 2000 | 4 | 0 |
| 2001 | 7 | 0 |
| 2002 | 4 | 6 |
| 2003 | 6 | 23 |
| 2004 | 1 | 20 |
| 2005 | 4 | 54 |
| 2006 | 2 | 15 |
| 2007 | 2 | 6 |
| 2008 | 3 | 11 |
| 2009 | 1 | 16 |
| 2010 | 6 | 5 |
| 2011 | 8 | 4 |
| 2012 | 7 | 10 |
| 2013 | 1 | 13 |
| 2014 | 4 | 9 |
| 2015 | 17 | 26 |
| 2016 | 5 | 30 |
| 2017 | 16 | 26 |
| 2018 | 17 | 24 |
| 2019 | 18 | 21 |
| 2020 | 14 | 22 |
| 2021 | 14 | 24 |
| 2022 | 12 | 22 |
| 2023 | 8 | 25 |
| 2024 | 5 | 21 |
| 2025 | 11 | 17 |
| 2026 | 5 | 13 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Recombinant bacteria and uses thereof18 Aug 2026US 12,708,650 B2National University of Singapore
- Genetically modified non-human animals expressing human EPO4 Aug 2026US 12,696,884 B2Institute for Research in Biomedicine (IRB)
- Anti-tumor fusion protein, preparation method therefor and application thereof24 Feb 2026US 12,558,403 B2Guangdong Taihe Medicine Science & Technology Co., Ltd
- Compositions and methods for potentiating immune activity17 Feb 2026US 12,551,555 B2Kumquat Biosciences Inc.
- Compositions and methods for modulating TTR expression6 Jan 2026US 12,516,319 B2Ionis Pharmaceuticals, Inc.
- CRISPR-Cas9 Knock-out of SHP-1/2 to Reduce T cell Exhaustion in Adoptive Cell Therapy24 Sep 2026US 2026/0286300 A1The Trustees of the University of Pennsylvania
- Protein tyrosine phosphatase wedge domain peptide dimer for nervous system repair24 Sep 2026US 2026/0286322 A1NervGen Pharma Corp.
- Fusion proteins for improved gene editing24 Sep 2026US 2026/0286397 A1New York Genome Center, Inc.
- Dna vaccine targeting overexpressed antigens in colorectal cancer10 Sep 2026US 2026/0263576 A1University of Washington
- Conjugated antisense compounds and their use27 Aug 2026US 2026/0250680 A1Ionis Pharmaceuticals, Inc.
Most cited
By later US patents
- Interfering RNA molecules134US 7,452,987 B2Silence Therapeutics GmbH · 2008
- Conjugated antisense compounds and their use122US 9,127,276 B2Isis Pharmaceuticals, Inc. · 2015
- Interfering RNA molecules77US 9,222,092 B2Silence Therapeutics GmbH · 2015
- Oligoribonucleotides with enzymatic activity72US 6,617,438 B1Sirna Therapeutics, Inc. · 2003
- Interfering RNA molecules63US 7,893,245 B2Silence Therapeutics GmbH · 2011